The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Primary Aldosteronism-Global Market Insights and Sales Trends 2024
Synopsis
Primary aldosteronism refers to the excess production of the hormone aldosterone from the adrenal glands, resulting in low renin levels. This abnormality is caused by hyperplasia or tumors. Many suffer from fatigue, potassium deficiency and high blood pressure which may cause poor vision, confusion or headaches.
The global Primary Aldosteronism market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Primary Aldosteronism in various end use industries. The expanding demands from the Hospitals, Specialty Clinic and Others,, are propelling Primary Aldosteronism market. Blood Test, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Imaging Test segment is estimated at % CAGR for the next seven-year period.
The treatment for hyperaldosteronism depends on the underlying cause. In people with a single benign tumor (adenoma), surgical removal (adrenalectomy) may be curative. This is usually performed laparoscopically, through several very small incisions. For people with hyperplasia of both glands, successful treatment is often achieved with spironolactone or eplerenone, drugs that block the effect of aldosterone.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Primary Aldosteronism, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Primary Aldosteronism market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Primary Aldosteronism market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Primary Aldosteronism sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Primary Aldosteronism covered in this report include Pfizer, Sun Pharmaceutical Industries, Bristol Laboratories, CMP Pharma, Koninklijke Philips, GE Healthcare, Siemens, Shimadzu Corporation and Canon, etc.
The global Primary Aldosteronism market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Sun Pharmaceutical Industries
Bristol Laboratories
CMP Pharma
Koninklijke Philips
GE Healthcare
Siemens
Shimadzu Corporation
Canon
Global Primary Aldosteronism market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Primary Aldosteronism market, Segment by Type:
Blood Test
Imaging Test
Global Primary Aldosteronism market, by Application
Hospitals
Specialty Clinic
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Primary Aldosteronism companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Primary aldosteronism refers to the excess production of the hormone aldosterone from the adrenal glands, resulting in low renin levels. This abnormality is caused by hyperplasia or tumors. Many suffer from fatigue, potassium deficiency and high blood pressure which may cause poor vision, confusion or headaches.
The global Primary Aldosteronism market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Primary Aldosteronism in various end use industries. The expanding demands from the Hospitals, Specialty Clinic and Others,, are propelling Primary Aldosteronism market. Blood Test, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Imaging Test segment is estimated at % CAGR for the next seven-year period.
The treatment for hyperaldosteronism depends on the underlying cause. In people with a single benign tumor (adenoma), surgical removal (adrenalectomy) may be curative. This is usually performed laparoscopically, through several very small incisions. For people with hyperplasia of both glands, successful treatment is often achieved with spironolactone or eplerenone, drugs that block the effect of aldosterone.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Primary Aldosteronism, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Primary Aldosteronism market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Primary Aldosteronism market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Primary Aldosteronism sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Primary Aldosteronism covered in this report include Pfizer, Sun Pharmaceutical Industries, Bristol Laboratories, CMP Pharma, Koninklijke Philips, GE Healthcare, Siemens, Shimadzu Corporation and Canon, etc.
The global Primary Aldosteronism market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Sun Pharmaceutical Industries
Bristol Laboratories
CMP Pharma
Koninklijke Philips
GE Healthcare
Siemens
Shimadzu Corporation
Canon
Global Primary Aldosteronism market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Primary Aldosteronism market, Segment by Type:
Blood Test
Imaging Test
Global Primary Aldosteronism market, by Application
Hospitals
Specialty Clinic
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Primary Aldosteronism companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Primary Aldosteronism
1.1 Primary Aldosteronism Market Overview
1.1.1 Primary Aldosteronism Product Scope
1.1.2 Primary Aldosteronism Market Status and Outlook
1.2 Global Primary Aldosteronism Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Primary Aldosteronism Market Size by Region (2018-2029)
1.4 Global Primary Aldosteronism Historic Market Size by Region (2018-2023)
1.5 Global Primary Aldosteronism Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Primary Aldosteronism Market Size (2018-2029)
1.6.1 North America Primary Aldosteronism Market Size (2018-2029)
1.6.2 Europe Primary Aldosteronism Market Size (2018-2029)
1.6.3 Asia-Pacific Primary Aldosteronism Market Size (2018-2029)
1.6.4 Latin America Primary Aldosteronism Market Size (2018-2029)
1.6.5 Middle East & Africa Primary Aldosteronism Market Size (2018-2029)
2 Primary Aldosteronism Market by Type
2.1 Introduction
2.1.1 Blood Test
2.1.2 Imaging Test
2.2 Global Primary Aldosteronism Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Primary Aldosteronism Historic Market Size by Type (2018-2023)
2.2.2 Global Primary Aldosteronism Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Primary Aldosteronism Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Primary Aldosteronism Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Primary Aldosteronism Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Primary Aldosteronism Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Primary Aldosteronism Revenue Breakdown by Type (2018-2029)
3 Primary Aldosteronism Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Specialty Clinic
3.1.3 Others
3.2 Global Primary Aldosteronism Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Primary Aldosteronism Historic Market Size by Application (2018-2023)
3.2.2 Global Primary Aldosteronism Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Primary Aldosteronism Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Primary Aldosteronism Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Primary Aldosteronism Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Primary Aldosteronism Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Primary Aldosteronism Revenue Breakdown by Application (2018-2029)
4 Primary Aldosteronism Competition Analysis by Players
4.1 Global Primary Aldosteronism Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Primary Aldosteronism as of 2022)
4.3 Date of Key Players Enter into Primary Aldosteronism Market
4.4 Global Top Players Primary Aldosteronism Headquarters and Area Served
4.5 Key Players Primary Aldosteronism Product Solution and Service
4.6 Competitive Status
4.6.1 Primary Aldosteronism Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Primary Aldosteronism Products, Services and Solutions
5.1.4 Pfizer Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Sun Pharmaceutical Industries
5.2.1 Sun Pharmaceutical Industries Profile
5.2.2 Sun Pharmaceutical Industries Main Business
5.2.3 Sun Pharmaceutical Industries Primary Aldosteronism Products, Services and Solutions
5.2.4 Sun Pharmaceutical Industries Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.2.5 Sun Pharmaceutical Industries Recent Developments
5.3 Bristol Laboratories
5.3.1 Bristol Laboratories Profile
5.3.2 Bristol Laboratories Main Business
5.3.3 Bristol Laboratories Primary Aldosteronism Products, Services and Solutions
5.3.4 Bristol Laboratories Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.3.5 CMP Pharma Recent Developments
5.4 CMP Pharma
5.4.1 CMP Pharma Profile
5.4.2 CMP Pharma Main Business
5.4.3 CMP Pharma Primary Aldosteronism Products, Services and Solutions
5.4.4 CMP Pharma Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.4.5 CMP Pharma Recent Developments
5.5 Koninklijke Philips
5.5.1 Koninklijke Philips Profile
5.5.2 Koninklijke Philips Main Business
5.5.3 Koninklijke Philips Primary Aldosteronism Products, Services and Solutions
5.5.4 Koninklijke Philips Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.5.5 Koninklijke Philips Recent Developments
5.6 GE Healthcare
5.6.1 GE Healthcare Profile
5.6.2 GE Healthcare Main Business
5.6.3 GE Healthcare Primary Aldosteronism Products, Services and Solutions
5.6.4 GE Healthcare Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.6.5 GE Healthcare Recent Developments
5.7 Siemens
5.7.1 Siemens Profile
5.7.2 Siemens Main Business
5.7.3 Siemens Primary Aldosteronism Products, Services and Solutions
5.7.4 Siemens Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.7.5 Siemens Recent Developments
5.8 Shimadzu Corporation
5.8.1 Shimadzu Corporation Profile
5.8.2 Shimadzu Corporation Main Business
5.8.3 Shimadzu Corporation Primary Aldosteronism Products, Services and Solutions
5.8.4 Shimadzu Corporation Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.8.5 Shimadzu Corporation Recent Developments
5.9 Canon
5.9.1 Canon Profile
5.9.2 Canon Main Business
5.9.3 Canon Primary Aldosteronism Products, Services and Solutions
5.9.4 Canon Primary Aldosteronism Revenue (US$ Million) & (2018-2023)
5.9.5 Canon Recent Developments
6 North America
6.1 North America Primary Aldosteronism Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Primary Aldosteronism Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Primary Aldosteronism Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Primary Aldosteronism Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Primary Aldosteronism Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Primary Aldosteronism Market Dynamics
11.1 Primary Aldosteronism Industry Trends
11.2 Primary Aldosteronism Market Drivers
11.3 Primary Aldosteronism Market Challenges
11.4 Primary Aldosteronism Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
